Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice

被引：18

作者：

Sekine, Masaaki ^{[1
]}

Kubuki, Yoko ^{[1
]}

Kameda, Takuro ^{[1
]}

Takeuchi, Masanori ^{[2
]}

Toyama, Takanori ^{[3
]}

Kawano, Noriaki ^{[4
]}

Maeda, Kouichi ^{[5
]}

Sato, Seiichi ^{[6
]}

Ishizaki, Junzo ^{[7
]}

Kawano, Hiroshi ^{[2
]}

Kamiunten, Ayako ^{[1
]}

Akizuki, Keiichi ^{[1
]}

Tahira, Yuki ^{[1
]}

Shimoda, Haruko ^{[1
]}

Shide, Kotaro ^{[1
]}

Hidaka, Tomonori ^{[1
]}

Kitanaka, Akira ^{[8
]}

Yamashita, Kiyoshi ^{[4
]}

Matsuoka, Hitoshi ^{[2
]}

Shimoda, Kazuya ^{[1
]}

机构：

[1] Univ Miyazaki, Dept Gastroenterol & Hematol, Fac Med, Miyazaki, Japan

[2] Koga Gen Hosp, Miyazaki, Japan

[3] Miyazaki Prefectural Nobeoka Hosp, Nobeoka, Japan

[4] Miyazaki Prefectural Miyazaki Hosp, Miyazaki, Japan

[5] Miyakonojo Med Ctr, Miyakonojo, Japan

[6] Fujimoto Genral Hosp, Miyakonojo, Japan

[7] Miyazaki Aisenkai Nichinan Hosp, Nichinan, Japan

[8] Kawasaki Med Sch, Dept Lab Med, Kurashiki, Okayama, Japan

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2017年 / 98卷 / 05期

关键词：

adult T-cell leukemia; lymphoma; antibody therapy; CC chemokine receptor 4; mogamulizumab; retrospective; LEUKEMIA-LYMPHOMA; PROGNOSTIC INDEX; ANTIBODY; CCR4; KW-0761;

D O I：

10.1111/ejh.12863

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ObjectiveThe efficacy of mogamulizumab in adult T-cell leukemia/lymphoma (ATLL) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real-life settings have demonstrated worse outcomes. MethodWe retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment. ResultsRelapsed/refractory ATLL patients with a median age of 70years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression-free survival (PFS) and overall survival (OS) from the start of mogamulizumab therapy were 1.8 and 4.0months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median PFS and OS durations of 2.7 and 8.5months, respectively. The median OS from diagnosis in relapsed/refractory ATLL patients receiving mogamulizumab was 12months, longer than the 5.8months in a historical cohort without mogamulizumab. ConclusionIn clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed/refractory ATLL, with an acceptable toxicity profile. Mogamulizumab therapy improved the OS of ATLL patients.

引用

页码：501 / 507

页数：7

共 50 条

[41] Mogamulizumab for the treatment of T-cell lymphoma [J].

Makita, Shinichi ;

Tobinai, Kensei .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (09) :1145-1153

[42] Genetic Alterations in Adult T-Cell Leukemia/Lymphoma: Novel Discoveries with Clinical and Biological Significance [J].

Sakihama, Shugo ;

Karube, Kennosuke .

CANCERS, 2022, 14 (10)

[43] Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T-Cell Leukemia-Lymphoma [J].

Shimazu, Yutaka ;

Murotani, Kenta ;

Kitabayashi, Hiroki ;

Nishio, Yukihiro .

HEMATOLOGICAL ONCOLOGY, 2025, 43 (04)

[44] Clinical characteristics of adult T-cell leukemia/lymphoma infiltration in the gastrointestinal tract [J].

Miike, Tadashi ;

Kawakami, Hiroshi ;

Kameda, Takuro ;

Yamamoto, Shojiro ;

Tahara, Yoshihiro ;

Hidaka, Tomonori ;

Kubuki, Yoko ;

Yorita, Kenji ;

Akiyama, Yutaka ;

Arimura, Yasuji ;

Kubota, Yoshimasa ;

Kataoka, Hiroaki ;

Shimoda, Kazuya .

BMC GASTROENTEROLOGY, 2020, 20 (01)

[45] CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment [J].

Sakamoto, Yuma ;

Ishida, Takashi ;

Masaki, Ayako ;

Murase, Takayuki ;

Yonekura, Kentaro ;

Tashiro, Yukie ;

Tokunaga, Masahito ;

Utsunomiya, Atae ;

Ito, Asahi ;

Kusumoto, Shigeru ;

Iida, Shinsuke ;

Ueda, Ryuzo ;

Inagaki, Hiroshi .

BLOOD, 2018, 132 (07) :758-761

[46] Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma [J].

Saito, Masato ;

Ishii, Toshihiko ;

Urakawa, Itaru ;

Matsumoto, Asuka ;

Masaki, Ayako ;

Ito, Asahi ;

Kusumoto, Shigeru ;

Suzuki, Susumu ;

Takahashi, Takeshi ;

Morita, Akimichi ;

Inagaki, Hiroshi ;

Iida, Shinsuke ;

Ishida, Takashi .

BLOOD ADVANCES, 2020, 4 (10) :2180-2191

[47] New treatments for adult T-cell leukemia/lymphoma [J].

Epstein-Peterson, Zachary D. ;

Gurumurthi, Ashwath ;

Horwitz, Steven M. .

LEUKEMIA RESEARCH, 2025, 149

[48] Diagnosis and management of adult T-cell leukemia/lymphoma [J].

Ishitsuka, Kenji .

SEMINARS IN HEMATOLOGY, 2021, 58 (02) :114-122

[49] Adult T-cell leukemia/lymphoma: A pending challenge [J].

Alvarez, Carolina ;

Beltran, Brady .

REVISTA DEL CUERPO MEDICO DEL HOSPITAL NACIONAL ALMANZOR AGUINAGA ASENJO, 2023, 16 (04)

[50] Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma [J].

Kameda, Takuro ;

Shide, Kotaro ;

Tahira, Yuki ;

Sekine, Masaaki ;

Sato, Seiichi ;

Ishizaki, Junzo ;

Takeuchi, Masanori ;

Akizuki, Keiichi ;

Kamiunten, Ayako ;

Shimoda, Haruko ;

Toyama, Takanori ;

Maeda, Kouichi ;

Yamashita, Kiyoshi ;

Kawano, Noriaki ;

Kawano, Hiroshi ;

Hidaka, Tomonori ;

Yamaguchi, Hideki ;

Kubuki, Yoko ;

Kitanaka, Akira ;

Matsuoka, Hitoshi ;

Shimoda, Kazuya .

VIRUSES-BASEL, 2022, 14 (04)

← 1 2 3 4 5 →